Bell Asset Management Ltd Buys Shares of 31,448 DexCom, Inc. $DXCM

Bell Asset Management Ltd purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 31,448 shares of the medical device company’s stock, valued at approximately $2,116,000.

Other hedge funds have also added to or reduced their stakes in the company. Andra AP fonden bought a new stake in DexCom during the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom during the 2nd quarter worth $26,000. SJS Investment Consulting Inc. lifted its position in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new stake in DexCom in the third quarter valued at about $29,000. Finally, Sound Income Strategies LLC grew its position in DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 285 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Evercore assumed coverage on shares of DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research note on Wednesday, February 25th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Finally, Truist Financial reissued a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Stock Down 3.7%

Shares of DXCM opened at $68.10 on Monday. The stock’s 50-day moving average price is $70.69 and its two-hundred day moving average price is $68.75. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a market capitalization of $26.21 billion, a PE ratio of 32.43, a PEG ratio of 1.32 and a beta of 1.48. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the company earned $0.45 earnings per share. The firm’s revenue was up 13.1% compared to the same quarter last year. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.